Bioscience Industry Recommends Revisions to the Clinical Trials Directive
Bioscience Industry Recommends Revisions to the Clinical Trials Directive
LONDON, UK, October 3, 2007-The BioIndustry Association (BIA) today expressed its support for a revision of the Clinical Trials Directive 2001/20/EC at the European Commission-EMEA Conference on the operation of the Clinical Trials Directive. The conference offered stakeholder representatives a platform to provide feedback on the implementation of the Clinical Trials Directive and offer recommendations for the future.
The BIA believes that the Clinical Trials Directive should be reviewed in order to achieve harmonisation, transparency, and consistency in the approval and conduct of clinical trials across EU Member States, whilst ensuring public health protection. This will facilitate efficient development of biopharmaceutical products in Europe, which would in turn have a direct benefit of improving patient access to innovative medicines. It should be emphasised that the entire Directive does not need to be repealed and replaced by a different legal instrument.
The BIA, working EuropaBio, the European association for the bioscience industry, has identified five key areas for improving the Clinical Trials Directive:
- It is necessary to modify the language used to reduce the flexibility of the provisions in the Directive. Currently, the provisions are open to misinterpretation and misapplication of the law by Member States.
- The current regulatory and ethics review processes should be streamlined to accelerate the initiation of trials and allow patients faster access to innovative treatments.
- The roles and scope of responsibilities of National Competent Authorities (NCAs) and Ethics Committees need to be more clearly defined.
- Mutual recognition of assessments carried out by NCAs should be introduced.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
